Boehringer Ingelheim International Gmbh

Gilead Sciences, Inc.

Lee Fader

Murray D Bailey

Rebekah J Carson

Youla S Tsantrizos

Bruno Simoneau

Stephen Kawai

Francois Bilodeau

Mathieu Parisien

Carl Thibeault

Sebastien Morin

Serge R Landry

Teddy Halmos

Marc-Andre Poupart

Christian Brochu

Simon Surprenant

Pierre Louis Beaulieu

Christiane Yoakim

Derek Cogan

Cédrickx Godbout

Daniel Richard Marshall

Martin Poirier

Bryan Patrick McKibben

Julie Naud

Jennifer Burke

Maude A Poirier

Cyrille Kuhn

André Giroux

Steven LaPlante

Rene Coulombe

Steven R Laplante

Olivier Lepage

Martin Duplessis

Clint A James

James Gillard

Yunlong Zhang

Zhidong Chen

Elisia Villemure

Benoît Moreau

Peter Allen Nemoto

Maolin Yu

Paul John Edwards

John Lord

Michael Balestra

Xin Guo

Chantal Grand-Maitre

Oliver Hucke

Hui Yu

Louis Morency

Marc Pesant

Megan Bertrand-Laperle

Simon Suprenant

Araz Jakalian

Sébastien Morin

Matthew A Cerny

Mélissa Leblanc

Steven Laplantea

Marc-André Joly

Thao Trinh

François Bilodeau

Kosea S Frederick

Punit-Kumar Bhardwaj

Maude Poirier

Bryan Mckibben

Bryan P Mckibben

A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: Xand Xare each independently CRor N; Ris H, (C)alkyl, (C)haloalkyl, halo. &#x2014;O&#x2014;(C)alkyl, NH, NH(C)alkyl or N((C)alkyl); Rand Rare each independently (C)alkyl optionally mono- or di-substituted with &#x2014;O&#x2014;(C)alkyl, NH, NH(C)alkyl or N((C)alkyl); or Rand R, together with the carbon to which they are attached, are linked to form a (C)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with &#x2014;(C)alkyl; Ris &#x2014;C(&#x2550;O)N(R)(R), &#x2014;C(&#x2550;O)O(R), heterocyclyl or heteroaryl, wherein each said heterocyclyl and heteroaryl is optionally substituted 1 to 3 times with R; Rand Rare each independently H or (C)alkyl optionally mono- or di-substituted with &#x2014;O&#x2014;(C)alkyl, NH, NH(C)alkyl or N((C)alkyl); or Rand R, together with the carbon to which they are attached, are linked to form a (C)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with &#x2014;(C)alkyl; and n is 0, 1 or 2. 

Hepatitis C inhibitor compounds

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Aldosterone synthase inhibitors

Compounds of Formula (I) wherein n, R, R, R, Rand Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

Compounds of Formula (I) wherein n, m, R, R, R, R, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Cytomegalovirus inhibitor compounds

Compounds of Formula (I) wherein n, R, R, R, R, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

Compounds of Formula (I) wherein n, A, R, R, Rand Rare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Compounds of formula I: wherein a, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

Compounds of formula I: wherein R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Compounds of formula (I): wherein c, X, Y, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula I: wherein c, R, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

The present invention relates to compounds of formula (I) wherein c, X, Y, R, R, Rand Rare as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.

Growing community of inventors

New Milford, CT, United States of America

Lee Fader